Extension of Confidentiality Period for R&D Payment from Vanda Pharmaceuticals
Extended the confidentiality period for R&D payment from Vanda Pharmaceuticals (joint drug development) from 2026-04-30 to 2026-05-31
Amount undisclosed (expected receipt within 45 days per contract), exceeding 10% of 2022 sales (approx. KRW 2.3 billion), mandatory disclosure
Initial disclosure: 2023-06-30; subsequent disclosures on 2025-09-15 and 2026-03-26 related to same matter
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related To Investment Decision (Receipt Of R&D Expenses For Joint Research And Development Of New Drug)